Why Nektar Therapeutics (NKTR) is on investor radar

Nektar Therapeutics (NKTR) has drawn fresh attention after recent trading saw the stock move against a backdrop of mixed performance, with a modest gain over the past month but a stronger recovery across the past 3 months.

At a latest share price of $78.43, Nektar’s recent pullback over the past week contrasts with an 18.2% 3 month share price return and a very large 1 year total shareholder return. Together, these figures suggest sentiment has shifted meaningfully compared with its longer term track record.

If you are looking beyond a single biotech stock, this could be a useful moment to size up other healthcare focused opportunities using our screener of 33 healthcare AI stocks

With Nektar’s share price already up strongly over the past year but still trading at a very large discount to the consensus price target, you have to ask: is there real upside left here, or is the market already pricing in future growth?

Most Popular Narrative: 46% Undervalued

At a last close of $78.43 against a fair value estimate of $144.25, the most followed Nektar narrative frames the recent rally as only part of the story.

Robust cash position after the recent equity raise extends runway into 2027, providing operational stability to advance late-stage assets and initiate Phase III trials without near-term dilution or financing risk. This supports earnings predictability and reduces financial leverage concerns.

Curious what has to happen between now and 2029 for that fair value to make sense? Revenue paths, margin shifts and a very demanding earnings multiple all sit at the core of this narrative.

Result: Fair Value of $144.25 (UNDERVALUED)

However, this hinges on rezpegaldesleukin delivering in larger Phase 3 trials and on Nektar managing ongoing losses without relying heavily on fresh equity funding.

Another Way to Look at Nektar’s Valuation

The analyst narrative points to a fair value of $144.25, yet Nektar trades on a P/S of 47.6x versus 4.8x for the US pharmaceuticals sector and a fair ratio of 19.4x. That big gap raises a simple question: is the upside story already embedded in today’s rich multiple?

Next Steps

Mixed signals so far, with strong optimism but clear concerns in the background, so check the data yourself, weigh both sides, and see the 1 key reward and 3 important warning signs

Looking for more investment ideas?

If Nektar has caught your attention, do not stop there. Use this momentum to broaden your watchlist and pressure test your next moves across other opportunities.

• Spot potential value by scanning a focused list of quality companies trading below their estimated worth with the help of 44 high quality undervalued stocks.
• Prioritise resilience by reviewing 69 resilient stocks with low risk scores that score well on stability, financial strength, and lower overall risk profiles.
• Hunt for tomorrow’s potential standouts before they hit the headlines with a screener containing 22 high quality undiscovered gems that filters for strong fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.